-- 万华化工集团(SHA:600309)尽管受到地缘政治紧张局势和伊朗战争带来的更多挑战的影响,2025年利润有所下滑,但仍寻求持续的国际扩张。 该公司周二在上海证券交易所发布的2025年业绩报告显示,归属于股东的净利润同比下降3.9%至125亿元人民币,即每股3.99元人民币。上年同期归属于股东的净利润约为130亿元人民币,即每股4.15元人民币。 营业收入同比增长12%,从1821亿元人民币增至2032亿元人民币。 万华在盈利报告中表示,尽管面临持续低迷的价格、关税上调以及与美国的贸易摩擦等外部挑战,中国石化行业在2025年仍保持稳定。 “通过持续投资技术创新、不断扩大全球布局以及深化完善的运营体系,公司保持了快速发展。”该公司在盈利报告中表示。 万华是二苯基甲烷二异氰酸酯(MDI)的主要生产商,MDI是一种用于生产聚氨酯产品的化学品。聚氨酯广泛应用于化工、纺织、建材和交通运输等各个行业。 2025年,该公司聚氨酯销售收入达193亿元人民币,销量约为170万吨(根据该公司提交的另一份交易所文件)。 万华石化产品销售收入为205亿元人民币,精细化工和新材料销售收入为103亿元人民币。 今年,石化行业面临更多挑战,尤其是在持续不断的中东战争导致全球油价暴跌的情况下。伊朗关闭霍尔木兹海峡,进一步加剧了全球石油供应紧张。然而,分析人士认为,中国拥有充足的石油储备来应对这场危机。 据路透社4月1日报道,中国第一季度石油日均进口量为540万桶,但据称其拥有秘密储备,足以替代通过霍尔木兹海峡进口的石油长达七个月。 中国也在考虑发展其他能源,例如可再生能源,这些能源在石油危机期间可能会获得更大的需求。 西太平洋银行国际经济主管埃利奥特·克拉克表示:“发达市场和发展中市场消费者和企业对当前能源价格飙升的反应几乎肯定会是加速对可再生能源产品和电动汽车的需求,而中国在这两方面都处于全球主导地位,并拥有充足的剩余产能来生产和运输这些产品。”
Related Articles
Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%
Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.
ASX Biggest Losers
Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07
Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal
Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.